

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development.

**FOR FURTHER INFORMATION CONTACT:**

Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager, National Center for Advancing Translational Sciences, NIH, 9800 Medical Center Drive, Rockville, MD 20850, Phone: 301-827-7181, or email [sury.vepa@nih.gov](mailto:sury.vepa@nih.gov). A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

**SUPPLEMENTARY INFORMATION:**

Technology description follows.

**Inhibitors of Phosphoinositide 3-Kinase and Histone Deacetylase for Treatment of Cancer**

*Description of Technology:* The invention includes compounds that act as dual inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC), including a core containing a quinazoline moiety or a quinazolin-4(3H)-one moiety, a kinase hinge binding moiety, and a histone deacetylase pharmacophore, a pharmaceutically acceptable salt thereof, a prodrug thereof, or solvate thereof. The present invention also provides compounds that are selective inhibitors of histone deacetylase inhibitor that include a core containing a quinazolin-4(3H)-one moiety and a histone deacetylase pharmacophore.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

*Potential Commercial Applications:*

- Novel therapeutics for cancers neurodegenerative diseases.
- *Competitive Advantages:*
  - Novel dual inhibitor compounds of this invention have a commercial advantage over those currently known

because they can act as selective and dual inhibitors of specific isoforms of HDAC (such as HDAC6) and PI3K (such as PI3K $\delta$ ) potentially providing better toxicity profile and therefore bigger therapeutic window.

*Development Stage:*

- Pre-Clinical (compound optimization and in vivo validation).

*Inventors:*

- Grewal, Gurmit; Thakur, Ashish; Tawa, Gregory James; Ferrer, Marc; and Simeonov, Anton M.

*Intellectual Property:* 1. INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER, PCT Patent Application NO. PCT/US2018/038507 filed on June 20, 2018 (HHS Ref. No. E-104-2017).

*Licensing Contact:* Sury Vepa, Ph.D., J.D. Phone: 301-827-7181, or email [sury.vepa@nih.gov](mailto:sury.vepa@nih.gov).

Dated: October 1, 2019.

**Lillianne M. Portilla Weingarten,**

*Technology Development Coordinator, National Center for Advancing Translational Sciences.*

[FR Doc. 2019-21965 Filed 10-7-19; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Center for Advancing Translational Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Advancing Translational Sciences Special Emphasis Panel; Drug Screening with Bio Fabricated 3-D Skin Disease Tissue Models.

*Date:* October 23, 2019.

*Time:* 2:00 p.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Rahat (Rani) Khan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, 6701 Democracy Blvd., Rm 1078, Bethesda, MD 20892, 301-894-7319, [khanr2@csr.nih.gov](mailto:khanr2@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: October 2, 2019.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-21851 Filed 10-7-19; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Eunice Kennedy Shriver National Institute of Child Health & Human Development; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the National Institute of Child Health and Human Development Special Emphasis Panel on Pediatric Trauma and Injury Prevention, which was published in the **Federal Register** on September 25, 2019, 84 FR 50460.

This meeting's location and format has changed from an in-person meeting at the Residence Inn, Bethesda MD to an IAT/Teleconference meeting at 6710B Rockledge Dr., Bethesda MD. The meeting is closed to the public.

Dated: October 2, 2019.

**Ronald J. Livingston, Jr.,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-21850 Filed 10-7-19; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Center for Scientific Review; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial

property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Fellowships: Genes, Genomes and Genetics.

*Date:* October 31–November 1, 2019.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015.

*Contact Person:* Lystranne Alysia Maynard Smith, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–402–4809, [lystranne.maynard-smith@nih.gov](mailto:lystranne.maynard-smith@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Fellowships: Sensory and Motor Neuroscience, Cognition and Perception.

*Date:* October 31–November 1, 2019.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

*Contact Person:* Cibu P Thomas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, Bethesda, MD 20894, 301–435–1042, [thomascp@mail.nih.gov](mailto:thomascp@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel PAR–17–169: Biomarkers: Bridging Pediatric and Adult Therapeutics.

*Date:* October 31, 2019.

*Time:* 11:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call)

*Contact Person:* Khalid Masood, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5120, MSC 7854, Bethesda, MD 20892, 301–435–2392, [masoodk@csr.nih.gov](mailto:masoodk@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel PAR Panel: Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity.

*Date:* October 31, 2019.

*Time:* 1:00 p.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Jin Huang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4095G, MSC 7812, Bethesda, MD 20892, 301–435–1230, [jh377p@nih.gov](mailto:jh377p@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel U.S.-South

Africa Program for Collaborative Biomedical Research—Phase 2 (HIV/AIDS).

*Date:* November 1, 2019.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* John C Pugh, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1206, MSC 7808, Bethesda, MD 20892, (301) 435–2398, [pughjohn@csr.nih.gov](mailto:pughjohn@csr.nih.gov).

*Name of Committee:* Genes, Genomes, and Genetics Integrated Review Group Genetics of Health and Disease Study Section.

*Date:* November 4–5, 2019.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Christopher Payne, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, 301–402–3702, [christopher.payne@nih.gov](mailto:christopher.payne@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Topics in Bacterial Pathogenesis.

*Date:* November 4, 2019.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015.

*Contact Person:* Richard G Kostriken, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3192, MSC 7808, Bethesda, MD 20892, 240–519–7808, [kostrikr@csr.nih.gov](mailto:kostrikr@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel PAR–19–222: Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional).

*Date:* November 5, 2019.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Jianxin Hu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2156, Bethesda, MD 20892, 301–827–4417, [jianxinh@csr.nih.gov](mailto:jianxinh@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel: The Blood-Brain Barrier, Neurovascular System and CNS Therapeutics.

*Date:* November 5, 2019.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Linda MacArthur, Ph.D., Scientific Review Officer, Center for

Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4187, Bethesda, MD 20892, 301–537–9986, [macarthurlh@csr.nih.gov](mailto:macarthurlh@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Shared and High-End Instruments: NMR and Crystallography.

*Date:* November 5, 2019.

*Time:* 11:00 a.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Sudha Veeraraghavan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–435–1504, [sudha.veeraraghavan@nih.gov](mailto:sudha.veeraraghavan@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: October 2, 2019.

**Ronald J. Livingston, Jr.,**  
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–21845 Filed 10–7–19; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Biomedical Computing and Health Informatics Study Section, October 10, 2019, 8:00 a.m. to October 11, 2019, 6:00 p.m. at the Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda MD 20814, which was published in the **Federal Register** on September 10, 2019, 84 FR 47528.

The Contact Person for this meeting has been changed to Karen Nieves Lugo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda MD, 20892, (301) 594–9088, [karen.nieveslugo@nih.gov](mailto:karen.nieveslugo@nih.gov). The meeting date, time and location remain the same. The meeting is closed to the public.

Dated: October 2, 2019.

**Miguelina Perez,**  
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–21849 Filed 10–7–19; 8:45 am]

**BILLING CODE 4140–01–P**